SubsidieMeestersReal-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgery
Thericon is developing an rMSI platform to enhance endoscopic cancer surgery by providing multi-parametric imaging for better tissue differentiation and reducing cancer recurrence, seeking funding for market launch in 2024.
Projectdetails
Introduction
Cancer is the leading cause of death in the EU, with 2.7M diagnoses and 1.3M deaths in 2020. Effective removal of cancerous tissue through endoscopic surgery is challenging because of limited visual and absent tactile information.
Challenges in Current Imaging Technologies
The limitations of current imaging technologies make it difficult for surgeons to differentiate between different types of tissue. This poses significant challenges in ensuring the complete removal of cancerous tissue during surgical procedures.
Thericon's Solution
For this market, Thericon is developing an rMSI (real-time multispectral imaging) platform. This platform provides surgeons with multi-parametric images that help with:
- Effective removal of cancerous tissue
- Reduction of cancer recurrence in patients
Product Development
The company has developed a prototype for its first product, named rMSI 2, and has completed initial validation for bladder cancer applications.
Funding Request
Thericon is asking for:
- A 2.5M EIC grant
- 5.5M equity funding
This funding will be used to complete clinical application pilots, safety tests, and CE certification for this product, getting it ready for market launch in 2024.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 4.092.151 |
Tijdlijn
| Startdatum | 1-10-2022 |
| Einddatum | 30-9-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- THERICON GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Multi4 - the first surgical instrument for bladder cancer treatment through a 20-minute outpatient procedureMulti4 is developing an innovative surgical instrument for bladder cancer treatment that enables outpatient procedures, enhancing patient care and reducing recurrence rates. | EIC Accelerator | € 2.493.000 | 2024 | Details |
Multi4 - the first surgical instrument for bladder cancer treatment through a 20-minute outpatient procedure
Multi4 is developing an innovative surgical instrument for bladder cancer treatment that enables outpatient procedures, enhancing patient care and reducing recurrence rates.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Multi-sensor Eversion Robot Towards Intelligent Endoscopic Diagnosis and TherapyEndoTheranostics aims to revolutionize colorectal cancer screening and treatment through a robotic system that enables painless preparation, real-time polyp detection, and effective removal using advanced imaging and tools. | ERC Synergy ... | € 7.616.426 | 2024 | Details |
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid TumoursScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027. | EIC Transition | € 2.499.911 | 2025 | Details |
Multimodal Hypersprectal Imaging and Raman Spectroscopy for Intraoperative Assessment of Breast Tumor Resection MarginsSpectra-BREAST aims to enhance tumor margin assessment in breast conserving surgery using a novel multimodal approach for real-time, accurate feedback, improving patient outcomes and reducing reoperation rates. | EIC Pathfinder | € 2.990.207 | 2024 | Details |
MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic careMIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally. | EIC Transition | € 2.495.127 | 2022 | Details |
MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENTMULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care. | EIC Pathfinder | € 2.863.733 | 2024 | Details |
Multi-sensor Eversion Robot Towards Intelligent Endoscopic Diagnosis and Therapy
EndoTheranostics aims to revolutionize colorectal cancer screening and treatment through a robotic system that enables painless preparation, real-time polyp detection, and effective removal using advanced imaging and tools.
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid Tumours
ScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027.
Multimodal Hypersprectal Imaging and Raman Spectroscopy for Intraoperative Assessment of Breast Tumor Resection Margins
Spectra-BREAST aims to enhance tumor margin assessment in breast conserving surgery using a novel multimodal approach for real-time, accurate feedback, improving patient outcomes and reducing reoperation rates.
MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic care
MIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally.
MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENT
MULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care.